Wedbush analyst Laura Chico downgraded Chinook Therapeutics to Neutral from Outperform with a $42 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on KDNY:
- Chinook Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo
- Chinook Therapeutics Announces First Patient Enrolled in Pivotal Phase 3 BEYOND Study of Zigakibart (BION-1301) for Patients with IgA Nephropathy
- Chinook announces first patient enrolled in Phase 3 BEYOND study of BION-1301
- Chinook Therapeutics presents data from CHK-336 Phase 1 trial
- Chinook Therapeutics Presents Data from CHK-336 Phase 1 Trial in Healthy Volunteers and New Insights into the Role of Failed Repair in Chronic Kidney Disease at the 60th European Renal Association (ERA) Congress